HemaSphere
(Aug 2023)
P1052: A REAL-WORLD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS
- Minghui Duan,
- Lan MA,
- Qiuling Wu,
- Hong Liang,
- Wei Wang,
- Shaoling Wu,
- Lijun Mu,
- Hai Lin,
- Hebing Zhou,
- Hongxia Shi,
- Hongmei Jing
Affiliations
- Minghui Duan
- 1 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Hematology, Beijing, China
- Lan MA
- 2 Peking University Third Hospital, Beijing, China
- Qiuling Wu
- 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Hong Liang
- 4 Clinical Research Center for Hematologic Disease, Harbin, China
- Wei Wang
- 5 Department of Hematology,The Hospital of Qingdao University, Qingdao, China
- Shaoling Wu
- 5 Department of Hematology,The Hospital of Qingdao University, Qingdao, China
- Lijun Mu
- 6 The Second Hospital of Dalian Medical University, Dalian, China
- Hai Lin
- 7 First Hospital Affiliated of Jilin University, Jilin, China
- Hebing Zhou
- 8 Beijing Luhe Hospital,Capital Medical University, Beijing, China
- Hongxia Shi
- 9 National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Beijing, China
- Hongmei Jing
- 2 Peking University Third Hospital, Beijing, China
- DOI
-
https://doi.org/10.1097/01.HS9.0000971104.15697.cd
- Journal volume & issue
-
Vol. 7
p.
e15697cd
WeChat QR code